Article

PD-1 Inhibitors are a game changer

Author(s):

Guest

Michael Wong, melanoma oncologist and CURE advisory board member, explains how recent studies are targeting the PD-1 pathway and describes why there is so much excitement surrounding this new class of immunotherapy.

Related Videos
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Related Content
Image of money.
April 3rd 2025

Survey Findings Reveal Financial Challenges in Patients with Cancer

Ryan Scott
Among patients with cancer, high out-of-pocket costs were found to impact access to health care, adherence to medication, as well as quality of life.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Illustration of women with brown hair.
April 3rd 2025

How Breast Cancer Taught Me Resilience in Unexpected Life Challenges

Natasha Carlson
Lessons I learned from a cancer diagnosis have been applied in some surprising and seemingly unrelated aspects of my life.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for further treatment expansion.
April 3rd 2025

Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial

Spencer Feldman
Immune response data from FLAMINGO-01 shows positive results in patients with HER2+ breast cancer, suggesting potential for further treatment expansion.
Illustration of ovaries.
April 3rd 2025

Development of Nemvaleukin for Platinum-Resistant Ovarian Cancer Halted

Alex Biese
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.